by | Mar 18, 2024 | Uncategorized
An FDA advisory committee voted that a pair of chimeric antigen receptor T-cell therapies should be approved for earlier line treatments in adults with relapsed or refractory multiple myeloma, although one produced far more deliberation.The committee determined the...
by | Mar 14, 2024 | Uncategorized
Source: CureToday articles Here is a run-down of some topics we covered in the Spring 2024 issue of CURE. Read More
by | Mar 13, 2024 | Uncategorized
Source: CureToday articles Eating a plant-based diet has been associated with sustained MRD negativity for patients with multiple myeloma. Read More
by | Mar 11, 2024 | Uncategorized
Source: CureToday articles The BCMA protein has become the primary target for treating multiple myeloma, resulting in longer survival and more manageable side effects. Read More
by | Mar 10, 2024 | Uncategorized
Source: CureToday articles This poem was written in hope that those experiencing multiple myeloma, or other cancers, will find solace in knowing that advancements in treatments are being made every day, and a positive attitude with caregiver acceptance and support...
by | Mar 7, 2024 | Uncategorized
The combination of belantamab mafodotin, pomalidomide and dexamethasone extended PFS compared with standard care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.Belantamab mafodotin (Blenrep, GSK) is an antibody-drug...
